Karen Daily, DO - Research

Research at a glance

Top areas of exploration

Breast Neoplasms , 10 publications
Neoplasms , 3 publications
Neoplasm Recurrence, Local , 3 publications
Antineoplastic Combined Chemotherapy Protocols , 3 publications

Research activity

40 publications

407 citations

Why is this important?

Active clinical trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 * early breast cancer with intermediate or high risk for disease recurrence who completed definitive鈥�

Investigator: Karen Daily
Status: Accepting Candidates
Ages: 18 Years - 130 Years
Sexes: All

My publications

40 publications

2025

Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast聽Cancer Patients Receiving Adjuvant Therapy.

JACC. CardioOncology

鈥�

2024

Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.

Clinical and translational science

鈥�

2024

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

JCO Precision Oncology

2023

Bilateral primary breast Burkitt's lymphoma in pregnancy.

BMJ case reports

鈥�

2023

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

Cancer reports (Hoboken, N.J.)

鈥�

BOB体育

Karen Daily, DO : Research

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast聽Cancer Patients Receiving Adjuvant Therapy.

Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

Bilateral primary breast Burkitt's lymphoma in pregnancy.

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

BOB体育

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast聽Cancer Patients Receiving Adjuvant Therapy.

Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

Bilateral primary breast Burkitt's lymphoma in pregnancy.

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.